Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Malignancies Multiple”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03700450
What this trial is testing

Cyclophosphamide as Graft-versus-host Prophylaxis After Allogeneic Stem Cell Transplantation for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Universitätsklinikum Hamburg-Eppendorf 37
Not applicableUnknownNCT02184897
What this trial is testing

Pharmacokinetic and Pharmacodynamic Study of Lenograstim for Hematopoietic Stem Cell Mobilization

Who this might be right for
Multiple Myeloma
Asan Medical Center 24
Large-scale testing (Phase 3)Study completedNCT02181413
What this trial is testing

Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant

Who this might be right for
Multiple MyelomaAutologous Stem Cell Transplant
Takeda 656
Not applicableNo Longer AvailableNCT00063791
What this trial is testing

Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Large-scale testing (Phase 3)Study completedNCT01215513
What this trial is testing

Long-Term Safety and Tolerability of Degarelix One-Month Dosing Regimen in Korean Patients

Who this might be right for
Prostate Cancer
Ferring Pharmaceuticals 127
Testing effectiveness (Phase 2)WithdrawnNCT00004040
What this trial is testing

Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy

Who this might be right for
LeukemiaMultiple Myeloma and Plasma Cell Neoplasm
Hoag Memorial Hospital Presbyterian
Testing effectiveness (Phase 2)Looking for participantsNCT04661137
What this trial is testing

Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 96
Early research (Phase 1)Study completedNCT00502164
What this trial is testing

Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer

Who this might be right for
Advanced Prostate Adenocarcinoma
AstraZeneca 40
Early research (Phase 1)Study completedNCT00006009
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

Who this might be right for
LymphomaSmall Intestine Cancer
Stanford University
Large-scale testing (Phase 3)UnknownNCT04401709
What this trial is testing

Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

Who this might be right for
Biliary Tract Cancer
Samsung Medical Center 490
Testing effectiveness (Phase 2)Active Not RecruitingNCT00869232
What this trial is testing

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

Who this might be right for
Multiple Myeloma
University of Arkansas 90
Early research (Phase 1)Looking for participantsNCT05139056
What this trial is testing

Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Who this might be right for
Currently Only Enrolling Glioblastoma Patients at First Recurrence
City of Hope Medical Center 36
Not applicableLooking for participantsNCT05518851
What this trial is testing

TreAtments and outComes in paTients With prImary CutAneous Lymphoma

Who this might be right for
Primary Cutaneous Lymphoma
Peking University First Hospital 3,000
Early research (Phase 1)Study completedNCT00060645
What this trial is testing

Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED)

Who this might be right for
TumorsLymphomaMultiple Myeloma
Merck Sharp & Dohme LLC 33
Testing effectiveness (Phase 2)Study completedNCT00003572
What this trial is testing

Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers

Who this might be right for
LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm+1 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 20
Not applicableStudy completedNCT00891657
What this trial is testing

Post Market Study for an Adhesion Barrier Following Laparoscopic Myomectomy

Who this might be right for
FibroidMyomaLeiomyoma
Integra LifeSciences Corporation 15
Testing effectiveness (Phase 2)Study completedNCT01989598
What this trial is testing

Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
National Cancer Institute (NCI) 25
Not applicableStudy completedNCT05306587
What this trial is testing

Daratumumab Provided at Home Experience An Open, Single-center, Mixed-method Project.

Who this might be right for
Multiple Myeloma
Thomas Lund 40
Testing effectiveness (Phase 2)WithdrawnNCT03841565
What this trial is testing

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Who this might be right for
Recurrent Plasma Cell Myeloma
Academic and Community Cancer Research United
Testing effectiveness (Phase 2)Study completedNCT01160107
What this trial is testing

Revlimid And Prednisone Followed By Revlimid, Melphalan And Prednisone In Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
Fondazione EMN Italy Onlus 46
Next Page